Safety of a Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Adults Aged 65 Years and Older

Phase 1, randomised, double-blind trial of MF59-adjuvanted quadrivalent influenza vaccine in influenza (4 arms), sponsored by Ab&B Bio-tech Co., Ltd. Primary endpoints: Incidence of adverse events (AEs) or reactions (ARs) within 30 minutes post-vaccination, Incidence of adverse events (AEs) or reactions (ARs) within 0-7 days post-vaccination and 3 more. Started Nov 2025; status: active, not recruiting.